Gilead Sciences is trading higher today as investors digest a series of positive clinical developments and research updates. The company recently announced a successful mid-stage trial for an oral bowel disease therapy and is set to present new data on rare liver diseases at The Liver Meeting 2026, building on momentum from its recent research presentations at IDWeek. This follows a period of analyst optimism, including a recent upgrade to a Zacks Rank #2 Buy rating driven by a 39.1% increase in consensus earnings estimates over the past three months, which helps offset the stock's 1.88% decline from the previous session.